583 documents

Read All
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD); progressive supranuclear palsy (PSP) Patient sample and fly studies suggest PIWIL1 overexpression or inhibiting viral DNA polymerases could help treat AD, PSP and other tauopathies. In postmortem cortex and cerebellum samples from...
Read More
23:57 , Jul 26, 2018 |  BC Innovations  |  Targets & Mechanisms

PureTech plumbs the brain

PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by...
Read More
16:11 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology; autoimmune disease

INDICATION: Alzheimer’s disease (AD); multiple sclerosis (MS); rheumatoid arthritis (RA) Patient sample, in vitro, cell culture and mouse studies identified a peptide-based inhibitor of the MYD88-TLR2 interaction that could help treat AD, MS, and RA. In...
Read More
19:52 , Jun 28, 2018 |  BC Innovations  |  Emerging Company Profile

Stress relief for neurons

Aquinnah Pharmaceuticals is developing disease-modifying therapies for amyotrophic lateral sclerosis and Alzheimer’s disease by inhibiting the formation of stress granules that promote protein aggregation in neurons. Stress granules are protein-RNA complexes assembled by RNA-binding proteins that...
Read More
20:22 , Jun 15, 2018 |  BC Week In Review  |  Company News

Eisai to open U.S.-based immunodementia discovery center

With a three-year $100 million investment, Eisai Inc. will launch the Eisai Center for Genetics Guided Dementia Discovery in Cambridge, Mass. Eisai Inc. is the U.S. subsidiary of Eisai Co. Ltd. (Tokyo:4523). The center, expected to...
Read More
22:05 , Jun 1, 2018 |  BioCentury  |  Finance

Bacterial brain

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B. The round closed on May 31 with...
Read More
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
Read More
18:45 , May 30, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs Tau mutations could help predict the risk of cancer. In 162 individuals from families with a history of tau mutations -- including N279K, ΔN296, P301L, V337M, V363A, T427M and a mutation that leads to...
Read More
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
Read More
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
Read More